Proparco, the subsidiary of the French Development Agency (AFD), continues to support the health sector. It has awarded grants to two major players in the private health sector in Morocco. These are the Oncology and Diagnostics Group of Morocco (ODM) and Amanys Pharma.
Since 2018, Proparco has been a shareholder and supports the development of the ODM group through a capital investment of 22 million dollars (more than MAD 200 million). As for Amanys Pharma, since last April it has benefited from 12 million dollars (more than MAD 100 million). “This targeted support provided to the ODM Group and to Amanys Pharma (formerly Saham Pharma) aims to cover the exceptional protection needs of patients and employees caused by the Covid-19 pandemic”, indicates the AFD subsidiary, adding that these grants were awarded with funds from the Ministry for Europe and Foreign Affairs.
These investments will promote the financing of protective equipment for employees and the improvement of patient reception in a health context degraded by the Covid-19 pandemic. The ODM group was formed around a set of clinics and centers specializing in the diagnosis and treatment of cancer.
As for Amanys Pharma, it is a pharmaceutical production and distribution company. The company specializes in the production of antibiotics for the general public, and the distribution of niche injectable treatments for the hospital sector.